2 recherche sur le mot-clé 'Anticonvulsant'

Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis / Tomoya HIROTA in Journal of Autism and Developmental Disorders, 44-4 (April 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.948-957 Titre : Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis Type de document : Texte imprimé et/ou numérique Auteurs : Tomoya HIROTA, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Eric HOLLANDER, Auteur ; Taro KISHI, Auteur Année de publication : 2014 Article en page(s) : p.948-957 Langues : Anglais (eng) Mots-clés : Antiepileptic  Mood stabilizer  Anticonvulsant  Autism  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities. En ligne : http://dx.doi.org/10.1007/s10803-013-1952-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 [article] Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis [Texte imprimé et/ou numérique] / Tomoya HIROTA, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Eric HOLLANDER, Auteur ; Taro KISHI, Auteur . - 2014 . - p.948-957. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.948-957 Mots-clés : Antiepileptic  Mood stabilizer  Anticonvulsant  Autism  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities. En ligne : http://dx.doi.org/10.1007/s10803-013-1952-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228

Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder / Jessica F. DOUGLAS in Journal of Autism and Developmental Disorders, 43-5 (May 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247 Titre : Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur Article en page(s) : p.1243-1247 Langues : Anglais (eng) Mots-clés : Antiepileptic  Anticonvulsant  Mood stabilizer  Sodium channel  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195 [article] Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur . - p.1243-1247. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247 Mots-clés : Antiepileptic  Anticonvulsant  Mood stabilizer  Sodium channel  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195